New Research Sorting Out Risk Genes for Brain Disorders
|
By LabMedica International staff writers Posted on 09 Mar 2017 |

Image
Using targeted gene sequencing in a large cohort population, researchers have discovered genes associated with higher risk of neurodevelopmental-disorders (NDDs), with some of those genes showing statistical biases for autism. The study provides new information about similarities and differences underlying various NDDs.
To identify and better understand gene-disrupting mutations related to NDDs, a team led by researchers of the laboratory of Evan Eichler, University of Washington Health Sciences/UW Medicine and Howard Hughes Medical Institute, conducted a large, international, multi-institutional study. More than 11,700 affected individuals and nearly 2,800 control subjects underwent targeted DNA sequencing of 208 suspected disease-risk genes, candidate genes that were chosen based on previously published studies. Samples were collected through the Autism Spectrum/Intellectual Disability 15-center network spanning 7 countries and 4 continents. An advantage of this collection is the ability to check back on a large fraction of cases in attempt to relate genetic results to clinical findings.
In their study population, the researchers associated 91 genes with risk of a NDD, including 38 genes not previously suspected. Based on some of the family studies, however, mutations even in two or more of the risk genes may not be necessary or sufficient to cause disease.
Of the 91 genes, 25 were linked with forms of autism without intellectual disability. The scientists also described a gene network that appeared to be related to high-functioning autism. Individuals with this form of autism have average to above average intelligence, but may struggle in learning to talk, interact socially, or manage anxiety and sensory overload. Additional findings suggest that less severe mutations may be behind autism that is not accompanied by intellectual disability. Also notable, although the overall numbers were low, was that several autism risk genes appeared predominantly in males, including some detected exclusively in males who had autism without intellectual impairment.
While observing that some genes were more closely associated with autism and others with intellectual or developmental impairments, the researchers found that most of the genes implicated were mutated in both conditions. This result reinforces previous studies indicating substantial overlap among NDDs in their underlying genetics and observable characteristics.
"Most of these genes are clearly risk factors for neurodevelopmental disorders in a broad sense," the researchers said, "But analysis of both the genetic and subsequent patient follow-up data did single out some genes with a statistical bias towards autism spectrum disorder, rather than an intellectual disability or developmental delay." By combining clinical and genetic data, the researchers observed patterns enabling them to begin to assess how some of the genes might function and how their disruption might lead to specific traits or symptoms.
The researchers also used Drosophila to investigate 21 genes to determine if any of the mutations disrupted a specific form of learning: habituation – growing accustomed to harmless stimuli. Problems with the neuronal mechanisms behind habituation are thought to account for some autism features, such as inability to filter sensory input. The Drosophila studies showed habituation deficits from several of the gene mutations under review, thereby providing additional evidence that they may have a role in cognitive function.
"The scientists are continuing this project and are eager to work with interested families," said University of Washington Prof. Raphael Bernier, clinical director of the Seattle Children's Autism Center. Families can contact the project team at rablab@uw.edu.
The study, by Stessman HAF et al, was published online February 13, 2017, in the journal Nature Genetics.
To identify and better understand gene-disrupting mutations related to NDDs, a team led by researchers of the laboratory of Evan Eichler, University of Washington Health Sciences/UW Medicine and Howard Hughes Medical Institute, conducted a large, international, multi-institutional study. More than 11,700 affected individuals and nearly 2,800 control subjects underwent targeted DNA sequencing of 208 suspected disease-risk genes, candidate genes that were chosen based on previously published studies. Samples were collected through the Autism Spectrum/Intellectual Disability 15-center network spanning 7 countries and 4 continents. An advantage of this collection is the ability to check back on a large fraction of cases in attempt to relate genetic results to clinical findings.
In their study population, the researchers associated 91 genes with risk of a NDD, including 38 genes not previously suspected. Based on some of the family studies, however, mutations even in two or more of the risk genes may not be necessary or sufficient to cause disease.
Of the 91 genes, 25 were linked with forms of autism without intellectual disability. The scientists also described a gene network that appeared to be related to high-functioning autism. Individuals with this form of autism have average to above average intelligence, but may struggle in learning to talk, interact socially, or manage anxiety and sensory overload. Additional findings suggest that less severe mutations may be behind autism that is not accompanied by intellectual disability. Also notable, although the overall numbers were low, was that several autism risk genes appeared predominantly in males, including some detected exclusively in males who had autism without intellectual impairment.
While observing that some genes were more closely associated with autism and others with intellectual or developmental impairments, the researchers found that most of the genes implicated were mutated in both conditions. This result reinforces previous studies indicating substantial overlap among NDDs in their underlying genetics and observable characteristics.
"Most of these genes are clearly risk factors for neurodevelopmental disorders in a broad sense," the researchers said, "But analysis of both the genetic and subsequent patient follow-up data did single out some genes with a statistical bias towards autism spectrum disorder, rather than an intellectual disability or developmental delay." By combining clinical and genetic data, the researchers observed patterns enabling them to begin to assess how some of the genes might function and how their disruption might lead to specific traits or symptoms.
The researchers also used Drosophila to investigate 21 genes to determine if any of the mutations disrupted a specific form of learning: habituation – growing accustomed to harmless stimuli. Problems with the neuronal mechanisms behind habituation are thought to account for some autism features, such as inability to filter sensory input. The Drosophila studies showed habituation deficits from several of the gene mutations under review, thereby providing additional evidence that they may have a role in cognitive function.
"The scientists are continuing this project and are eager to work with interested families," said University of Washington Prof. Raphael Bernier, clinical director of the Seattle Children's Autism Center. Families can contact the project team at rablab@uw.edu.
The study, by Stessman HAF et al, was published online February 13, 2017, in the journal Nature Genetics.
Latest Molecular Diagnostics News
- Plasma Protein Signature Predicts Lung Cancer Risk Up to Five Years Ahead
- Circulating Tumor DNA Testing Guides Chemotherapy, Reduces Relapse in Colon Cancer
- Researchers Uncover Distinct Chromosome Signature in Aggresive ALT Cancers
- Simple Cytogenetic Method Could Improve Classification of ALL Subtypes
- Blood-Based Assay Enables Noninvasive Monitoring of Sarcoma Immunotherapy Response
- Genomic Test Guides Chemotherapy Decisions in Early-Stage Breast Cancer
- Tumor Mutation Marker Helps Refine Lung Cancer Prognosis and Guide Therapy Selection
- Multi-Cancer Test Boosts Detection When Added to Standard Screening
- Blood-Based MRD Monitoring Supports Relapse Prevention in Leukemia
- Genomic Test Predicts Chemotherapy Benefit in Metastatic Prostate Cancer
- Blood Protein Markers Flag Multiple Sclerosis Risk Years Before Diagnosis
- Digital PCR Assays Support Surveillance of Bundibugyo Ebolavirus Outbreak
- Updated Guidance Prioritizes Stool-Based Colorectal Cancer Screening Tests
- Blood-Based Proteomic Test May Predict Treatment Response in Non-Small Cell Lung Cancer
- Position Statements Outline Evidence Standards for Multi-Cancer Detection Tests
- Ultrasensitive MRD Blood Test Detects Early Breast Cancer Recurrence
Channels
Clinical Chemistry
view channel
Saliva-Based Test Detects Biochemical Signs of Sleep Loss
Acute sleep loss impairs cognition and motor skills, raising safety risks that resemble alcohol intoxication. Clinicians currently lack an objective biochemical test to determine when someone is dangerously... Read more
Simple Dual-Tau Blood Test Detects and Stages Alzheimer’s Disease
Alzheimer’s disease is typically confirmed and staged with positron emission tomography scans and cerebrospinal fluid testing, procedures that are costly and invasive. Broader access to minimally invasive... Read more
Alzheimer’s Blood Biomarkers Linked to Early Cognitive Differences Before Dementia
Blood-based screening for Alzheimer’s disease offers a noninvasive, lower-cost alternative to brain imaging or spinal fluid testing, yet its ability to flag the earliest cognitive changes has been unclear.... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channelAptamer-Based Biosensor Enables Mutation-Resilient SARS-CoV-2 Detection
Rapid evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can undermine existing molecular diagnostics, especially when assays target small viral components. Double-antibody sandwich... Read more
Study Points to Autoimmune Pathway Behind Long COVID Symptoms
Long COVID leaves many SARS-CoV-2 survivors with persistent fatigue, cognitive issues, palpitations, and musculoskeletal pain for months or years. Estimates cited in new research suggest 4%–20% of infected... Read more
Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read moreMicrobiology
view channel
Gut Microbiome Signatures Help Identify Risk of IBD Progression
Inflammatory bowel disease (IBD), encompassing Crohn’s disease and ulcerative colitis, is a chronic relapsing inflammatory disorder of the gastrointestinal tract with highly variable outcomes.... Read more
FDA-Cleared Gastrointestinal Panel Detects 24 Pathogen Targets
Clinical guidelines support testing based on patient presentation in suspected gastrointestinal infections, yet available technologies have often forced laboratories to choose between panels that are too... Read morePathology
view channel
3D Spatial Multi-Omics Maps Intra-Tumor Diversity in Colorectal Cancer
Colorectal cancer remains a leading cause of cancer death, and clinical decision-making is complicated by marked intra-tumor heterogeneity. Conventional bulk sequencing averages molecular signals across... Read more
Blood-Based Method Tracks Gene Activity in the Living Brain
Real-time measurement of gene activity in the brain has been limited by assays requiring destructive tissue sampling. Tracking active genes could reveal how the body responds to environmental factors,... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel








